Risk Assessment of Co-treatment with Rifampicin and Tenofovir on Renal Function of Male Albino Rats
Abstract
Background: Tuberculosis is one of the comorbid infections commonly associated with human immunodeficiency virus which could necessitate the concurrent use of tenofovir and rifampicin (TDF-RIF). These drugs are individually associated with renal toxicity; hence concurrent use might be detrimental to renal function.
Objectives: This study, comparatively evaluated the toxicological effects of treatments with tenofovir, rifampicin and tenofovir- rifampicin combination on renal function of male albino rats.
Materials and Methods: Healthy adult male albino rats used for this study were divided into five (5) groups of sixteen animals (16) each. Animals in group A (placebo control) and group B (solvent control) were treated orally with water and arachis oil respectively. Animals in groups C-E were treated orally with 80mg/kg of rifampicin, 32 mg/kg of tenofovir and tenofovir-rifampicin combination for 1-8 weeks respectively. Animals were weighed and sacrificed at the end of drug treatment, blood samples were collected, centrifuged and serum extracted for creatinine, urea, uric acid, albumin, total protein and glucose evaluation. Animals were dissected kidneys were collected and weights determined.
Results: Treatment with tenofovir-rifampicin combination did not produce significant (p>0.05) effects on body and relative kidney weights, albumin, total protein and glucose levels when compared to their individual doses. Furthermore, insignificant (p>0.05) and time-dependent increases in serum creatinine, urea and uric acid levels were obtained in animals treated with combined doses of TDF-RIF when compared to their individual doses.
Conclusion: These results showed that concurrent use of tenofovir and rifampicin in the management of human immunodeficiency virus and tuberculosis co-infection may not be associated with synergistic renal toxicity at the dose levels used.
Keywords: Renal, Toxicity, Co- treatment, Tenofovir, Rifampicin, Rats
References
Abraham P, Ramamoorthy H, and Isaac B (2013). Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate-induced mitochondrial damage and increased oxido-nitrosative stress in the kidney, J. Biomed. Sci. 20: 3-15.
Adaramoye OA, Adewumi O M, Adesanoye OA, Faokunla O O, Farombi E O (2012). Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E. J. Basic Clin. Physiol. Pharmacol. 23: 69-75.
Adaramoye OA, OM. Adewumi, OA, Adesanoye , OO. Faokule, EO. Farombi. (2012) Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E. J. Basic Clin. Physiol. Pharmacol, 23: 69–75
Adikwu E, Ijeoma O, Edikpo N, Oputiri D, Geoffrey OP, (2013). Tenofovir Renal Toxicity: Evaluation of Cohorts and Clinical Studies—Part One, Pharmacology & Pharmacy. 4:651-662.
Adikwu E, Onyedenyifa OJ, Bibowei A (2016). Remedial Effects of Vitamins C and E on Atazanavir/Ritonavir-Induced Alterations in Biomarkers of Renal Function and Oxidative Stress of Male Albino Rats. Int. J. Biomed. Res. 7:193-200.
Adikwu EI, Ogbuehi NJ, Edikpo D, Oputiri PG. Oru-Bo, (2014). Tenofovir Renal Toxicity: Evaluation of Cohorts and Clinical Studies—Part 2 Pharmacology & Pharmacy 5:97-111.
Aminiafshar S, Alimagham M, Abbasi F, Fard-Khani SK (2009). Acute interstitial nephritis associated with rifampicin therapy. Saudi J. Kidn. Dis. Transplant. 20:1079-1080,
Antoniou T, Raboud JM, Chirhin S, Yoong D, Govan V, et al(2005). Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study HIV. Med. 6: 284–290
Asangansi E, Oshin AO, Akinloye OA. Drug nephrotoxicity. Ifemed J Med. (2005); Available at:
http://www.imeasangansi.org/pdf/drug%20nephrotoxicity.pdf.
Centers for Disease Control and Prevention. Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. Morb. Mort. Monthly Rep. 52. 2003
Choudhury D and Ahmed Z (2006). Drug-associated renal dysfunction and injury. Nature Clin. Pract. Nephrol. 2: 80-91
De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameir NH (1998) Rifampicin associated acute renal failure: pathophysiologic, immunologic and clinical features. Am. J. Kidn. Dis. 31:108-15,
Ferguson MA and Waikar SS (2012). Established and Emerging Markers of Renal Function. Clin. Chem. 58: 680- 689.
Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, et al, (2011) Tenofovir nephrotoxicity: 2011 update. AIDS Research and Treatment, Vol.2011, Article ID. 354908, 2011
Garcia-Cohen EC, Marin J, Diez-Picazo LD, Baena AB, Salaices M, Rodriguez-Martinez MA (2000). Oxidative stress induced by tert-butylhydroperoxide causes vasoconstriction in the aorta from hypertensive and aged rats: role of cyclooxygenase- 2 isoform. J. Pharmacol. Exp. Ther. 293: 75-81.
Geo FB, Karen CC, Butel JS, Morse SA, Timothy AM. Melnick and Alderberg”s Medical Microbiology: McGrawhill, 2010
Havey TC, Cserti-Gazdewich C, Sholzberg M, (2012). Keystone JS, and Gold WL, Case Report: Recurrent Disseminated Intravascular Coagulation Caused by Intermittent Dosing of Rifampin Am. J. Trop. Med. Hyg. 86: 264–267,
Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, and Markowitz GS (2010). Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidn. Int. 78: 1171 – 1177.
Izzedine H, Rad MB, Bardier A, et al, (2007). Atazanavir crystal nephropathy. AIDS. 21:2357–2358.
International, national and institutional guidelines for care and use of laboratory animals in biomedical research as promulgated by the Canadian Council of Animal Care (2009).
Jover-Saenz A, Porcel-Perez JM, Madrona AB, Bielsa-Martin S (2006). Acute interstitial nephritis due to rifampicin. Enferm. Infect. Microbiol. Clin. 24:64.
Kohler J, Hosseini S, Hoying-Brandt A (2009). Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 89: 513 – 519.
Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA (2009). Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J. Acq. Immune Def. Syndr, 51: 158– 163.
Lyseng-Williamson KA, Reynolds NA, Plosker GL (2005). Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 65: 413–432.
Mahmoud AM, Morsy BM, Abdel-Hady DS, Samy RM (2015). Prunus armeniaca Leaves Extract Protects against Isoniazid and Rifampicin Induced Nephrotoxicity through Modulation of Oxidative stress and Inflammation. Int. J. Food Nutr. Sci. 2:1-6
Michael B, Yano B, Sellers RS, Perry R, Morton D, Roome N et al, (2007). Evaluation of Organ Weights for Rodent and Non-Rodent Toxicity Studies: A Review of Regulatory Guidelines and a Survey of Current Practices. Toxicologic. Pathol. 35: 742-750.
Miller WG, Myers E., Ashwood AA, Killeen E, Wang LM, et al, (2005). Creatinine Measurement State of the Art in Accuracy and Interlaboratory Harmonization. Arch. Pathol. Lab Med, 3: 297-304,
Opromolla DVA (1992). Adverse Reactions to Rifampicin with special reference to acute renal failure, Hansen. Int. 17: 5- 7.
Patel K, Patel AK, Rajan RR and Patel AR (2010). Tenofovir associated renal dysfunction in clinical practice: An observational cohort from western India Ind. J. Sex Transm. Dis. 31: 30-34.
Patel KK, Patel A, Ranjan, R, Patel AR, Patel, J (2010) tenofovir associated renal dysfunction in clinical practice: observational cohort from western India. Ind. Sex Transm. Dis and AIDs, 31 (1) 30-34,
Patil SB, Kodliwadmath MV, Kodliwadmath MS (2007). Study of oxidative stress and enzymatic antioxidants in normal pregnancy, Ind. J. Clin. Biochem. 22:135-137.
Perazella MA (2010). Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy Kidney Intern 78: 1060 – 1063,
Peters DE and Chike AO (2013). Effect of rifampicin on the kidney of albino rats. J. App. Sci. Env. Man. 17: 125-131.
Peter SA (1991). Electrolyte disorders and renal dysfunction in acquired immunodeficiency syndrome patients. J. Nat. Med. Assoc. 83: 889-91.
Pozniak AL, Coyne MN, Miller RK , Lipman MC, Freedman, Ormerod ARF, Johnson LP et al, (2011). HIV British HIV Association guidelines for the treatment of TB/HIV co-infection. Med. 12: 517–524,
Prabu M Shagirtha SK, Renugadevi J (2010) Quercetin in combination with vitamins (C and E) improves oxidative stress and renal injury in cadmium intoxicated rats Eur. Rev. Med. Pharm. Sci. 14: 903-914
Ramamoorthy H, Abraham P and Isaac B (2012). Oxidative stress, decreased activities of anti-oxidant enzymes, and neutrophil infiltration contribute to Tenofovir disoproxil fumarate induced renal damage in rats. Int. Res. Pharm. Pharm. 10: 259-270.
Ramamoorthy H, Abraham P and Isaac B (2014). Preclinical efficacy of melatonin in the amelioration of tenofovir nephrotoxicity by the attenuation of oxidative stress, nitrosative stress, and inflammation in rats J. Basic Clin. Physiol. Pharmacol. 1-13.
Recknagel RO, Glende EA , Dolak JA , Waller RL (1989) Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther. 43: 139-154.
Rekha VV, Santha T, Jawahar MS, (2005). Rifampicin-induced Renal Toxicity during Retreatment of Patients with Pulmonary Tuberculosis. J. Assoc. Phys. India 53: 811-813,
Rosati S, Cherubini C, Iacomi F, Giannakakis K (2013). Acute rifampicin-associated interstitial tubulopathy in a patient with pulmonary tuberculosis, J. Med Case Reports, 7:106,
Rudra T, Webb BD, Evans AG (1989). Acute tubular necrosis following co-trimoxazole therapy. Nephron 53: 85–6,
Salih BM, Kharal M, Qahtani M, Dahneem L, Nohair S,. (2008)Acute interstitial nephritis induced by intermittent use of rifampicin in patient with brucellosis. Saudi J. Kidn. Dis. Transplant. 19: 450–452,
Sax PE, Gallant JE, Klotman PE (2007). Renal safety of tenofovir disoproxil fumarate. AIDS Reader 17: 99-104,
Schleenvoigt BT, Stallmach A, Pletz MW (2011). Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function. Eur. J. Med. Res. 16: 564,
Shabana MB, Ibrahim M, Khadre EM, Elemam MG, (2012). Influence of rifampicin and tetracycline dministration on some biochemical and histological parameters in albino rats. J. Basic Appl. Zool. 65: 299–308,
Sutar VS, Patil SS, Pishvikar SA and More HN (2012). Spectrophotometric method for degradation study of tenofovir disopoxil fumarates. Int. J. Pharm. Sci. Res. 3: 4363-4366.
Tada OA, Nagai Y, Otani M, Ger TC, Kawamura SA, (1994). Case report of nephrotic syndrome associated with rifampicin therapy. Japan J. Nephrol. 37: 145–150.
Tende JA, Ezekiel I, Dikko AU and Goji AD. (2011). Effect of Ethanolic Leaves Extract of Moringaoleifera on Blood Glucose Levels of streptozocin-Induced Diabetics and Normoglycemic Wistar Rats. Brit J. Pharm Tox. 2: 1-4
Viread [tenofovir disoproxil fumarate] package insert. Foster City, CA: Gilead Sciences, 2001 Revised 2013
Vivet-Boudou V, Didierjean J, Ise C, et al, (2006). Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell. Mol. Life Sci. 63:163–186,
Warner SD. Nephrotic syndrome in rhesus monkeys. (1975). Abstracts of cases presented at the 25th Annual meeting American college of veterinary pathologists. Vet. Pathol. 12: 61–73.
World Health Organisation (2012) Technical update on treatment optimization Use of tenofovir in HIV-infected children and adolescents: a public health perspective.
Full Text: PDF
Refbacks
- There are currently no refbacks.